Women with confirmed physiological menopause without current anti-cancer treatment (group A), or women with menopausal symptoms in the context of aromatase inhibitors used as adjuvant therapy for hormone-sensitive non-metastatic breast cancers regardless of physiological menopause before the cancer diagnosis (group B)
Age 40-65 years
Body mass index 25-40 kg/m2
Stable weight (± 2 kg) over the previous month
Eating window ≥ 12 hours (self-reported and measured during the run-in phase)
Able to give informed consent and follow the study procedures for the entire duration
Confident use of a smartphone and able to take regular pictures of food/drinks
You may not be if
On a hypocaloric restrictive diet, intermittent fasting or in a weight management program over the previous month
Previous bariatric surgery or planned during the study
Active eating disorder(s) or major mental illness at inclusion
Psychoactive treatment with recent or planned changes of drug compound or dosage
Treatments affecting body weight (e.g. glucocorticoids, GLP-1 receptor analogues)
Diabetes with hypoglycemic drug(s) will be excluded, however those with prediabetes (as defined by the American Diabetes Association) or diabetes with no risk of hypoglycemia (i.e. treated with non-hypoglycemic drugs or without medication) will be included
Active metabolic bone diseases (e.g. Paget disease, osteomalacia), however women with osteoporosis will be included
Shift work comprising night shifts (working between 11pm and 6am) over the previous 2 weeks or planned during the study
Travel/trip to a different time zone (≥ 2-hour time difference) over the previous 2 weeks or planned during the study
Enrolled in another interventional clinical trial (medication, surgery, medical device) over the previous 2 weeks or planned during the study
Clareo Health | Time-Restricted Eating in Menopause and HOrmone-sensitive Breast Cancers (TREMHO)
